Charles River Laboratories CRL Net debt / EBITDA

Net debt / EBITDA at other companies

Labcorp HoldingsLH

2.9×-0.6×

Sotera HealthSHC

7.8×-0.3×

Fortrea Holdings Inc.FTRE

14.1×—

RevvityRVTY

4×+1.2×

IQVIAIQV

4.2×+0.1×

Quest DiagnosticsDGX

2.6×-0.4×

FAQ

What is Charles River Laboratories's net debt / EBITDA?

Charles River Laboratories (CRL) reported net debt / EBITDA of 4.2× in Q2 2026.

How has Charles River Laboratories's net debt / EBITDA changed year-over-year?

Charles River Laboratories's net debt / EBITDA increased by 23.0% year-over-year, from 3.4× to 4.2×.

What is the long-term trend for Charles River Laboratories's net debt / EBITDA?

Over 5 years (2020 to 2025), Charles River Laboratories's net debt / EBITDA has grown at a 3.3% compound annual growth rate (CAGR), from 2.9× to 3.4×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.